Stocktoria
Adaptimmune Therapeutics PLC ADAPY
Adaptimmune Therapeutics PLC (ADAPY) earns a Piotroski F-score of 3/9 (weak financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2024 revenue was $178.0M at a -39.8% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.503 |
| Retained earnings / assets | -4.448 |
| EBIT / assets | -0.28 |
| Equity / liabilities | 0.051 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| ADAPY | Adaptimmune Therapeutics PLC | 3/9 | -13.03 | — | +195.3% |
| RGNX | REGENXBIO Inc. | 3/9 | -7.82 | — | +104.5% |
| GLUE | Monte Rosa Therapeutics, Inc. | 4/9 | 1.67 | — | +63.5% |
| ATRA | Atara Biotherapeutics, Inc. | 4/9 | — | 2.9 | -6.3% |
| VXRT | Vaxart, Inc. | 5/9 | -4.73 | 8.3 | +726.7% |
| AGEN | AGENUS INC | 2/9 | — | — | +10.4% |
| IBRX | ImmunityBio, Inc. | 4/9 | — | — | +668.3% |
About Adaptimmune Therapeutics PLC
Adaptimmune Therapeutics plc engages in research, development, and subsequent manufacture and commercialisation of cell therapies to treat cancer in the United States and the United Kingdom. The company was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
FAQ
Is ADAPY financially healthy?
Adaptimmune Therapeutics PLC's Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does ADAPY pay a dividend?
No, Adaptimmune Therapeutics PLC does not currently pay a dividend.
How profitable is ADAPY?
In FY2024, Adaptimmune Therapeutics PLC had a net margin of -39.8% and a return on equity of -597.6%.
Is ADAPY a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Adaptimmune Therapeutics PLC: a Piotroski F-score of 3/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2024-12-31. Facts plus Stocktoria's own computed scores — not investment advice.